DC/I540/KLH vaccine (Dana-Farber Cancer Institute)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDC/I540/KLH vaccine (Dana-Farber Cancer Institute)

Drug Alias Nametelomerase: 540-548 peptide vaccinehTERT:540-548dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine

ClassificationVaccines > Development/production technology > Synthetic peptide vaccineVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Dendritic cell vaccine

Mechanisms of ActionTelomerase reverse transcriptase inhibitors

TargetsTelomerase reverse transcriptase

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Pennsylvania Dana-Farber Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesDana-Farber Cancer Institute University Of Pennsylvania

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A